TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8693426

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 100
Study: 1931401

Group type: EXPERIMENTAL
Intervention: Fentanyl-naloxone (F-Nal)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Fentanyl-normal saline (F-NS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal saline-naloxone (NS-Nal)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal saline-normal saline (NS-NS)
Number of subjects: 71
Study: 6982055

Group type: EXPERIMENTAL
Intervention: Co-trifamole (TMP and sulphamoxole)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Co-trimoxazole (TMP and sulphonamide)
Number of subjects: 10
Study: 31361837

Group type: EXPERIMENTAL
Intervention: Educational video intervention with a 1-page asthma question prompt list
Number of subjects: 359

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 359
Study: 30150464

Group type: EXPERIMENTAL
Intervention: Single i.v. doses of 0.1 to 3 mg/kg of body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 days of treatment with 0.5 or 1.5 mg/kg every 24 h (q24h) over 30 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg q24h over 60 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg/kg q12h over 60 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 0
Study: 27117887

Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release (LAR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (LAR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Transsphenoidal surgery
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Number of subjects: 7
Study: 24247736

Group type: EXPERIMENTAL
Intervention: Phthalate exposure during pregnancy
Number of subjects: 482
Study: 22703751

Group type: EXPERIMENTAL
Intervention: Osteopathic Fascial Manipulation (OFM)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham treatment (Control)
Number of subjects: 140
Study: 20415898

Group type: EXPERIMENTAL
Intervention: Belatacept (more intensive regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belatacept (less intensive regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study: 18613274

Group type: EXPERIMENTAL
Intervention: Robotic appendectomy
Number of subjects: 107
Study: 16521851

Group type: EXPERIMENTAL
Intervention: Purified oxygenated water (EXP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control water (CON)
Number of subjects: 9
Study: 12072852

Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cervical spinal manipulation
Number of subjects: 36
Study: 10691270

Group type: EXPERIMENTAL
Intervention: Triple regimen (senna syrup, Picolax, Klean Prep)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Fleet Phospho-soda
Number of subjects: 132
Study: 9071429

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day orally for 28 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thalidomide (300 mg/day for an additional month)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prednisone (for the patient who failed thalidomide therapy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Follow-up to 20 months
Number of subjects: 12
Study: 8178700

Group type: EXPERIMENTAL
Intervention: Parents' former smoking
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Family characteristics (family disunion, parents' awareness of child's activities)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Independent model
Number of subjects: 719
Study: 3087709

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous enteral alimentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 0
Study: 31728618

Group type: EXPERIMENTAL
Intervention: CCRT with PG2 injection (Astragalus polysaccharides) administered three times per week
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CCRT with PG2 injection
Number of subjects: 17

Group type: COMPARATOR
Intervention: CCRT with placebo
Number of subjects: 17
Study: 30396454

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (7-day dosage)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Long-acting GnRH agonist (single dose)
Number of subjects: 563
Study: 28083720

Group type: EXPERIMENTAL
Intervention: Social stressor (Trier Social Stress Test)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 56
Study: 25970838

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 84

Group type: COMPARATOR
Intervention: PLEX
Number of subjects: 84
Study: 23910743

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 31
Study: 20306195

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m²
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m²
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both doses (1.0 and 1.3 mg/m²)
Number of subjects: 42
Study: 18333598

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) + placement of chlorhexidine chip (PC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 11
Study: 16552342

Group type: EXPERIMENTAL
Intervention: Ximelagatran 36 mg orally twice daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0
Number of subjects: 130
Study: 12666712

Group type: EXPERIMENTAL
Intervention: Immediate Functional Loading (IFL) for 422 implants
Number of subjects: 152

Group type: COMPARATOR
Intervention: Immediate Non-Functional Loading (INFL) for 224 implants
Number of subjects: 152
Study: 11967788

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (AT(1)-receptor blocker)
Number of subjects: 0
Study: 9375707

Group type: EXPERIMENTAL
Intervention: Olestra
Number of subjects: 89

Group type: COMPARATOR
Intervention: Triglycerides
Number of subjects: 89
Study: 10146578

Group type: EXPERIMENTAL
Intervention: Single-use 7 French bioptome (Group I)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Reusable 8 French bioptome (Group II)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cost of single-use bioptome
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cost of reusable bioptome
Number of subjects: 63
Study: 30461202

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Number of subjects: 134

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 134
Study: 29110675

Group type: EXPERIMENTAL
Intervention: Lactoferrin and lysozyme daily supplement
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 25463375

Group type: EXPERIMENTAL
Intervention: Multi-electrode renal sympathetic denervation (RDN)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (12 resistant hypertensives matched for office BP)
Number of subjects: 31
Study: 25714215

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 30

Group type: COMPARATOR
Intervention: AAS
Number of subjects: 30
Study: 21689116

Group type: EXPERIMENTAL
Intervention: Interpersonal context that supported psychological needs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpersonal context that did not support psychological needs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goal conditions that supported psychological needs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Goal conditions that did not support psychological needs
Number of subjects: 0
Study: 20191582

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg administered intravenously every 4 weeks)
Number of subjects: 190
Study: 17668880

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha (pegIFN‐alpha) plus ribavirin
Number of subjects: 70
Study: 15793107

Group type: EXPERIMENTAL
Intervention: micafungin (12.5 to 200 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 74
Study: 12496978

Group type: EXPERIMENTAL
Intervention: Surgical resection of distal urethral web
Number of subjects: 0
Study: 9814460

Group type: EXPERIMENTAL
Intervention: 123I/99mTc‐sestamibi subtraction SPECT
Number of subjects: 19
Study: 7897962

Group type: EXPERIMENTAL
Intervention: ECCE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: phaco/suture
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: phaco/tunnel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: inexperienced surgeons
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: experienced surgeons
Number of subjects: 120

Group type: COMPARATOR
Intervention: prophylactic medication (levobunolol, acetazolamide, apraclonidine)
Number of subjects: 120
Study: 2706176

Group type: EXPERIMENTAL
Intervention: 1% halothane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% enflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% enflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% isoflurane
Number of subjects: 40
Study: 811704

Group type: EXPERIMENTAL
Intervention: Cyclandelate (Cyclospasmol), 400 mg four times daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30636000

Group type: EXPERIMENTAL
Intervention: High ADHD screening score
Number of subjects: 340

Group type: COMPARATOR
Intervention: Low ADHD screening score
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Age, motorcycling records, mean of riding hours per day
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: ADHD screening
Number of subjects: 340
Study: 28454807

Group type: EXPERIMENTAL
Intervention: Clinical decision support tool (CDS) integrated in electronic health record
Number of subjects: 444347

Group type: COMPARATOR
Intervention: Control group (no CDS intervention)
Number of subjects: 444347
Study: 26560727

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 41
Study: 25338498

Group type: EXPERIMENTAL
Intervention: rRT+APG101 (400 mg weekly i.v.)
Number of subjects: 91

Group type: COMPARATOR
Intervention: rRT (36 Gy; five times 2 Gy per week)
Number of subjects: 91
Study: 22311178

Group type: EXPERIMENTAL
Intervention: CHOICE program (voluntary after-school program)
Number of subjects: 9528
Study: 19530944

Group type: EXPERIMENTAL
Intervention: Nephroscopic stone fragmentation (group 1, n = 22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cystoscopic stone fragmentation (group 2, n = 21)
Number of subjects: 43
Study: 17513803

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (1 mg/kg/d orally) plus interferon alfa (3 x 10(6) U subcutaneously three times per week)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid plus interferon alfa
Number of subjects: 66
Study: 15078261

Group type: COMPARATOR
Intervention: Amodiaquine (AQ) 10 mg/kg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Artesunate (AR) 4 mg/kg first day then half dose
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQAR)
Number of subjects: 87
Study: 11771678

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (250 mg to 2,000 mg over 10 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (n = 2)
Number of subjects: 10
Study: 9684731

Group type: EXPERIMENTAL
Intervention: Met66 residue in K.IV type 10 of apo(a)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Thr66 residue in K.IV type 10 of apo(a)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Symptomatic atherosclerosis
Number of subjects: 308
Study: 7519567

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 25 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACET) 250 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 2657616

Group type: EXPERIMENTAL
Intervention: Amikacin (800 mg/m2/day) and ticarcillin‐clavulanate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vancomycin (1.2 g/m2/day), amikacin, and ticarcillin
Number of subjects: 14
Study: 31987235

Group type: EXPERIMENTAL
Intervention: Foot reflexology applied twice a week for 6 weeks (30-40 min per session)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 63
Study: 31500422

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg orally (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Number of subjects: 39
Study: 28939492

Group type: EXPERIMENTAL
Intervention: TC-containing wash products
Number of subjects: 154

Group type: COMPARATOR
Intervention: No-TC-containing wash products
Number of subjects: 154
Study: 25799793

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 75
Study: 23800177

Group type: EXPERIMENTAL
Intervention: Fixed dose combination therapy (polypill)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Current care
Number of subjects: 513
Study: 22760901

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate IV infusion (2 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline IV infusion
Number of subjects: 20
Study: 19953931

Group type: EXPERIMENTAL
Intervention: CD147 expression in prostate cancer
Number of subjects: 101

Group type: COMPARATOR
Intervention: CD147 expression in benign prostatic hyperplasia
Number of subjects: 101

Group type: COMPARATOR
Intervention: CD147 expression in normal prostate
Number of subjects: 101

Group type: COMPARATOR
Intervention: CD147 expression in embryonic prostate
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Association of CD147 expression with TNM stage
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Association of CD147 expression with depth of prostatic capsule invasion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Association of CD147 expression with histological grade
Number of subjects: 101
Study: 17888966

Group type: EXPERIMENTAL
Intervention: Single aortic cross‐clamp technique
Number of subjects: 107

Group type: COMPARATOR
Intervention: Multiple aortic cross‐clamp technique
Number of subjects: 107

Group type: COMPARATOR
Intervention: Off‐pump CABG
Number of subjects: 107
Study: 16106594

Group type: EXPERIMENTAL
Intervention: Melagatran-ximelagatran (subcutaneous melagatran for 1-2 days followed by oral ximelagatran for 6-9 days)
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Ximelagatran (oral for 7-12 days)
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Melagatran-ximelagatran
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Ximelagatran
Number of subjects: 14000
Study: 12021628

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/day for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10079409

Group type: EXPERIMENTAL
Intervention: Human preimplantation embryos cultured in vitro with endometrial stromal cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human preimplantation embryos cultured alone
Number of subjects: 0
Study: 7497865

Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg/day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16296701

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Captopril (25-50 mg twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 40
Study: 6212561

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (10%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol-free benzoyl peroxide gel
Number of subjects: 0
Study: 31104962

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy initiated within 61 days
Number of subjects: 16335

Group type: COMPARATOR
Intervention: Adjuvant therapy initiated after 61 days
Number of subjects: 16335
Study: 28142285

Group type: EXPERIMENTAL
Intervention: Physical activities programme (N = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition (N = 9)
Number of subjects: 19
Study: 25381429

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) at 375 mg/m² × 4
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) followed by Azathioprine (AZA) at 2 mg/kg/d after 3-6 months
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) followed by Azathioprine (AZA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both RTX and CYC/AZA
Number of subjects: 102
Study: 23883177

Group type: EXPERIMENTAL
Intervention: AFLY5 intervention
Number of subjects: 0
Study: 21834404

Group type: EXPERIMENTAL
Intervention: Ease of retrieval of autobiographical events (participants retrieved 6 or 12 personal memories)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reminder of the original number of recalled memories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discounting or augmenting ease of retrieval
Number of subjects: 0
Study: 19244470

Group type: EXPERIMENTAL
Intervention: Prednisolone only (PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No acyclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17095924

Group type: EXPERIMENTAL
Intervention: PRE-POST group (supplement consumed immediately before and after RE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRE-POST group
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOR-EVE group (supplement consumed in the morning and late evening)
Number of subjects: 0
Study: 14999649

Group type: EXPERIMENTAL
Intervention: Profile-tailored CBT
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study: 11159017

Group type: EXPERIMENTAL
Intervention: Bronchial macrophages from asthmatics with >5% airway eosinophils (AEo+)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bronchial macrophages from asthmatics
Number of subjects: 20
Study: 9644630

Group type: EXPERIMENTAL
Intervention: Active lupus nephritis patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-lupus nephropathies patients
Number of subjects: 0
Study: 8190480

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (60 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral acetaminophen (650 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral ibuprofen (600 mg)
Number of subjects: 60
Study: 3351819

Group type: EXPERIMENTAL
Intervention: One-minute alcohol wash followed by iodophor-impregnated adhesive film
Number of subjects: 79

Group type: COMPARATOR
Intervention: Five-minute iodophor scrub followed by iodophor wash
Number of subjects: 79
Study: 29931804

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention with two MI sessions
Number of subjects: 99

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 99
Study: 28222631

Group type: COMPARATOR
Intervention: 20 ml US‐TAP block (50 mg bupivacaine + 10 ml saline solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 ml US‐TAP block (50 mg bupivacaine + 20 ml saline solution)
Number of subjects: 60
Study: 25877874

Group type: EXPERIMENTAL
Intervention: Increased dose and frequency of albendazole and ivermectin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard dosage of ivermectin and albendazole
Number of subjects: 70
Study: 23668478

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21499018

Group type: EXPERIMENTAL
Intervention: Community-based fall assessment
Number of subjects: 369

Group type: COMPARATOR
Intervention: Hospital-based fall assessment
Number of subjects: 369
Study: 19199847

Group type: EXPERIMENTAL
Intervention: Telehealth intervention using Health Buddy(R) device for symptom management
Number of subjects: 0
Study: 16724993

Group type: EXPERIMENTAL
Intervention: H(2)-receptor antagonist half-dose group
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: H(2)-receptor antagonist full-dose group
Number of subjects: 483

Group type: COMPARATOR
Intervention: Control group (no maintenance therapy)
Number of subjects: 483
Study: 15289097

Group type: EXPERIMENTAL
Intervention: Azathioprine (3mg/kg/d for 12 weeks) plus prednisolone (reducing course starting at 40mg/d for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prednisolone (reducing course starting at 40mg/d for 12 weeks)
Number of subjects: 40
Study: 11422333

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) at 800 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) at 2400 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nondrug average
Number of subjects: 34
Study: 8997461

Group type: EXPERIMENTAL
Intervention: mexiletine 600 mg/d
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 7688950

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation for ischemic central vein occlusion
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Macular grid-pattern photocoagulation for macular edema
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Indeterminate group
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Perfused group
Number of subjects: 725
Study: 3281307

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5 mg (0.5 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline 0.5 mg (0.5 ml)
Number of subjects: 20